Montag A & Associates Inc Alnylam Pharmaceuticals, Inc. Transaction History
Montag A & Associates Inc
- $2.09 Billion
- Q3 2024
A detailed history of Montag A & Associates Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Montag A & Associates Inc holds 5 shares of ALNY stock, worth $1,323. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5
Previous 5
-0.0%
Holding current value
$1,323
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALNY
# of Institutions
654Shares Held
111MCall Options Held
2.14MPut Options Held
1.91M-
Capital World Investors Los Angeles, CA16.5MShares$4.37 Billion0.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.6MShares$3.34 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.53 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.64 Billion0.28% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.24MShares$1.39 Billion0.31% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $32.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...